Crystalline Management’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Crystalline Management’s Portfolio FSTX Stock Details FSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-375,000	Closed	-$2.37M	–	133
2022 Q4	$2.37M	Buy	+375,000	New	+$2.08M	1.19%	29

Crystalline Management's FSTX Position: Q1 2023 in Review

Crystalline Management sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 375,000 shares — an estimated $2.37M sold.

Crystalline Management first reported a position in FSTX in Q4 2022 and held it in 1 quarter. The position peaked at $2.37M in Q4 2022. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.

Crystalline Management reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Crystalline Management sold 375,000 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $2.37M.
Crystalline Management first reported a position in F-star Therapeutics, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
Crystalline Management's F-star Therapeutics, Inc. Common Stock position peaked at $2.37M in Q4 2022.
0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Crystalline Management's 13F filing for Q1 2023, filed 9 May 2023.